SNU-5 In Vitro Post-translational Modifications Assay

This assay is to provide SNU-5-based In Vitro Post-translational Modifications Assay to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.

SNU-5

Human

SNU-5 was line derived in 1987 by J. Park and associates from ascites of a patient with poorly differentiated carcinoma of the stomach. The patient had previously received chemotherapy including 5-fluorouracil, doxorubicin and mitomycin-C.
Derived from metastatic site, ascites

Gastric Carcinoma

Oncology

In Vitro Post-translational Modifications Assay

SNU-5-cell based In Vitro Post-translational Modifications Assay

Immunoassays and mass spectrometry techniques are considered ideal techniques for the detection of post-translational modification. Both the genetic and epigenetic modifications have contributed to the initiation and progression of cancer.

Gene and Protein Expression Assays

Following transcription, primary transcript RNA is converted into mature RNA by post-transcriptional modifications. Post-transcriptional modification includes three major steps namely the addition of a 5'cap, addition of a 3'polyadenylation tail and RNA splicing. Stability of RNA has been considered as very important for gene expression and proteins at the post-transcriptional level.